A Study to Assess the Safety, Tolerability, and Pharmacology of Darifenacin in Patients With ALS

NCT06249867 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

30

Enrollment

OTHER

Sponsor class

Conditions

Amyotrophic Lateral Sclerosis

Interventions

DRUG: Darifenacin 7.5 MG Extended Release Oral Tablet
DRUG: Placebo

Sponsor

Oliver Blanchard

Collaborators

[object Object]